BioLineRx Ltd. (BLRX) has a negative trailing P/E of -9.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -10.86%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -130.4 | 0.00 | 58.99 | 0.00 | - |
| 2017 | -162.6 | 45.52 | 74.86 | 0.00 | - |
| 2018 | -82.7 | 3.72 | 45.97 | 0.00 | - |
| 2019 | -34.5 | 2.42 | 26.32 | 0.00 | - |
| 2020 | -56.6 | 1.70 | 77.13 | 0.00 | - |
| 2021 | -133.3 | 2.02 | 52.97 | 0.00 | - |
| 2022 | -48.8 | 2.32 | 23.95 | 0.00 | - |
| 2023 | -66.5 | -0.70 | 305.02 | 840.27 | - |
| 2024 | -74.1 | 0.84 | 50.79 | 23.63 | - |
| 2025 | -9.6 | -0.06 | 0.63 | 9.57 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-4.20 | $0.00 | $-15.84M | - |
| 2017 | $-4.05 | $0.00 | $-24.35M | - |
| 2018 | $-3.15 | $0.00 | $-22.96M | - |
| 2019 | $-2.70 | $0.00 | $-26.81M | - |
| 2020 | $-1.80 | $0.00 | $-30.93M | - |
| 2021 | $-0.64 | $0.00 | $-28.14M | - |
| 2022 | $-0.40 | $0.00 | $-20.75M | - |
| 2023 | $-0.94 | $4.8M | $-60.61M | -1262.8% |
| 2024 | $-0.12 | $28.94M | $-9.22M | -31.9% |
| 2025 | $-0.29 | $1.19M | $-1.18M | -99.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.55 | $-0.56 – $-0.54 | $1.49M | $1.47M – $1.52M | 1 |
| 2027 | $-0.34 | $-0.34 – $-0.33 | $2.01M | $1.94M – $2.08M | 1 |
| 2028 | $-0.68 | $-0.69 – $-0.67 | $3.76M | $3.71M – $3.82M | 1 |
| 2029 | $-0.63 | $-0.64 – $-0.62 | $7.4M | $7.29M – $7.5M | 1 |
| 2030 | $-0.35 | $-0.36 – $-0.34 | $17.26M | $17.01M – $17.51M | 1 |
